PTC, after multiple FDA rejections, will try again with Translarna
19 Mar 2024
Accelerated Approval
Preview
Source: FiercePharma
PTC TherapeuticsPTC Therapeutics has suffered multiple rejections of its Duchenne muscular dystrophy drug at the FDA but will try for approval again after receiving "recent feedback" from the agency.
Despite Translarna's troubled history at the FDA—and a recent regulatory stumble in Europe—PTC Therapeutics once again hopes to convince U.S. regulators of the value of its Duchenne muscular dystrophy (DMD) therapy.
Tuesday, the company revealed that it plans to resubmit Translarna to the FDA for the treatment of nonsense mutation DMD by the middle of the year. The decision is based on "recent feedback" and comes after FDA rejections of the drug in 2016 and 2017.
In its first rejection of the drug, the FDA told the company the application wasn't sufficiently complete. In the second rejection, the agency raised flags about a lack of clinical evidence and other shortfalls in PTC's filing.
More recently, European regulators in January issued a negative opinion on renewing the DMD drug's authorization nearly a decade after its debut there. That decision came after a negative recommendation in September 2023 and a multi-month appeal process.
In deciding against renewing the drug's authorization, Europe's Committee for Medicinal Products for Human Use looked at Translarna’s data from the placebo-controlled Study 041, plus other trials. In Study 041, the PTC drug failed to meet statistical significance on its primary endpoint in a selected patient subgroup, but it did turn in "nominally statistically significant results on several key endpoints," the company argued.
The study's primary endpoint looked at changes from baseline in a six-minute walking distance test. Even as PTC stood behind the medicine, the European Medicines Agency stated bluntly that the study "failed to confirm Translarna's effectiveness."
After the Study 041 results dropped, the FDA told the company that the new trial doesn't provide enough evidence of benefit to support a resubmission, according to a PTC quarterly filing from last year. In response, PTC said it would request a meeting with the agency "to review the “totality of data collected to date."
On a recent conference call, Klein said the company had a meeting scheduled for this month with the agency.
Besides the Translarna development, PTC on Tuesday said it has submitted a biologics license application for Upstaza to treat aromatic L-amino acid decarboxylase deficiency to the FDA.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.